Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Overview
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
Chapter 6. Global Blood Plasma Derivatives Market, by Type
6.1 Overview
6.2 Factor VIII Concentrate
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
6.3 Factor IX Concentrate
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
6.4 Albumin
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
6.5 Immune Globulins
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
6.6 Anti-Thrombin III Concentrate
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
6.7 Fresh Frozen Plasma (FFP)
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
Chapter 7 Global Blood Plasma Derivatives Market, by Application
7.1 Overview
7.2 HIV
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
7.3 Hemophilia A
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
7.4 Hemophilia B
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
7.5 Hepatitis B
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
7.6 Hepatitis C
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
7.7 Bleeding disorders
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
7.8 Hypogammaglobulinemia
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
7.9 Immunodeficiency Diseases
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
7.10 Others
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
Chapter 8 Global Blood Plasma Derivatives Market, by End User
8.1 Overview
8.2 Hospitals & Clinics
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
8.3 Blood Transfusion Centers
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
8.4 Diagnostic Centers
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
8.5 Others
Market Estimates & Forecast, by Region, 2024-2032
Market Estimates & Forecast, by Country, 2024-2032
Chapter 10. Global Blood Plasma Derivatives Market, by Region
10.1 Overview
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 Latin America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa
Chapter 11. Company Landscape
11.1 Overview
11.2 Competitive Analysis
Chapter 12. Company Profile
12.1 Baxter BioScience
12.1.1 Company Overview
12.1.2 Product Type Overview
12.1.3 Financial Overview
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.2 Grifols S.A.
12.2.1 Company Overview
12.2.2 Product Type Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 CSL Behring
12.3.1 Company Overview
12.3.2 Product Type Overview
12.3.3 Financial Overview
12.3.4 Key Developments
12.3.5 SWOT Analysis
12.4 ViroPharma, Inc.
12.4.1 Company Overview
12.4.2 Product Type Overview
12.4.3 Financial Overview
12.4.4 Key Developments
12.4.5 SWOT Analysis
12.5 Talecris Biotherapeutics, Inc.
12.5.1 Company Overview
12.5.2 Product Type Overview
12.5.3 Financial Overview
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.6 Octapharma
12.6.1 Company Overview
12.6.2 Product Type Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.7 Fusion Healthcare
12.7.1 Overview
12.7.2 Product Type Overview
12.7.3 Financial Overview
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 SK Plasma Co., Ltd.
12.8.1 Overview
12.8.2 Product Type Overview
12.8.3 Financial Overview
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.9 Biotest AG
12.9.1 Overview
12.9.2 Product Type Overview
12.9.3 Financial Overview
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.10 Green Cross Corporation
12.10.1 Overview
12.10.2 Product Type Overview
12.10.3 Financial Overview
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.11 Shire Plc
12.11.1 Overview
12.11.2 Product Type Overview
12.11.3 Financial Overview
12.11.4 Key Developments
12.11.5 SWOT Analysis
12.13 Others
Chapter 13 Appendix
13.1 References
13.2 Related Reports
LIST OF TABLES
Table 1 Global Blood Plasma Derivatives Market Synopsis, 2024-2032
Table 2 Global Blood Plasma Derivatives Market Estimates and Forecast, 2024-2032 (USD Billion)
Table 3 Global Blood Plasma Derivatives Market, by Type, 2024-2032 (USD Billion)
Table 4 Global Blood Plasma Derivatives Market, by Applications, 2024-2032 (USD Billion)
Table 5 Global Blood Plasma Derivatives Market, by End users, 2024-2032 (USD Billion)
Table 6 Global Blood Plasma Derivatives Market, by Region, 2024-2032 (USD Billion)
Table 7 North America: Blood Plasma Derivatives Market, by Type, 2024-2032 (USD
Table 8 North America: Blood Plasma Derivatives Market, by Applications, 2024-2032 (USD
Table 9 North America: Blood Plasma Derivatives Market, by End users, 2024-2032 (USD
Table 10 US: Blood Plasma Derivatives Market, by Type, 2024-2032 (USD Billion)
Table 11 US: Blood Plasma Derivatives Market, by Applications, 2024-2032 (USD Billion)
Table 12 US: Blood Plasma Derivatives Market, by End users, 2024-2032 (USD Billion)
Table 13 Canada: Blood Plasma Derivatives Market, by Type, 2024-2032 (USD Billion)
Table 14 Canada: Blood Plasma Derivatives Market, by Applications, 2024-2032 (USD Billion)
Table 15 Canada: Blood Plasma Derivatives Market, by End users, 2024-2032 (USD Billion)
Table 16 Latin America: Blood Plasma Derivatives Market, by Type, 2024-2032 (USD Billion)
Table 17 Latin America: Blood Plasma Derivatives Market, by Applications, 2024-2032 (USD Billion)
Table 18 Latin America: Blood Plasma Derivatives Market, by End users, 2024-2032 (USD Billion)
Table 19 Europe: Blood Plasma Derivatives Market, by Type, 2024-2032 (USD Billion)
Table 20 Europe: Blood Plasma Derivatives Market, by Applications, 2024-2032 (USD Billion)
Table 21 Europe: Blood Plasma Derivatives Market, by End users, 2024-2032 (USD Billion)
Table 22 Western Europe: Blood Plasma Derivatives Market, by Type, 2024-2032 (USD Billion)
Table 23 Western Europe: Blood Plasma Derivatives Market, by Applications, 2024-2032 (USD Billion)
Table 24 Western Europe: Blood Plasma Derivatives Market, by End users, 2024-2032 (USD Billion)
Table 25 Eastern Europe: Blood Plasma Derivatives Market, by Type, 2024-2032 (USD Billion)
Table 26 Eastern Europe: Blood Plasma Derivatives Market, by Applications, 2024-2032 (USD Billion)
Table 27 Eastern Europe: Blood Plasma Derivatives Market, by End users, 2024-2032 (USD Billion)
Table 28 Asia-Pacific: Blood Plasma Derivatives Market, by Type, 2024-2032 (USD Billion)
Table 29 Asia-Pacific: Blood Plasma Derivatives Market, by Applications, 2024-2032 (USD Billion)
Table 30 Asia-Pacific: Blood Plasma Derivatives Market, by End users, 2024-2032 (USD Billion)
Table 31 Middle East & Africa: Blood Plasma Derivatives Market, by Type, 2024-2032 (USD Billion)
Table 32 Middle East & Africa: Blood Plasma Derivatives Market, by Applications, 2024-2032 (USD Billion)
Table 33 Middle East & Africa: Blood Plasma Derivatives Market, by End users, 2024-2032 (USD Billion)  
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Market Structure of the Global Blood Plasma Derivatives Market
Figure 3 Market Dynamics of the Global Blood Plasma Derivatives Market
Figure 5 Global Blood Plasma Derivatives Market, by Type, 2024-2032 (USD Billion)
Figure 6 Global Blood Plasma Derivatives Market, by Applications, 2024-2032 (USD Billion)
Figure 7 Global Blood Plasma Derivatives Market, by End users, 2024-2032 (USD Billion)
Figure 8 Global Blood Plasma Derivatives Market, by Region, 2024-2032 (USD Billion)
Figure 9 North America: Blood Plasma Derivatives Market Share, by Country, 2023 (%)
Figure 10 Europe: Blood Plasma Derivatives Market Share, by Region, 2023 (%)
Figure 11 Western Europe: Blood Plasma Derivatives Market Share, by Country, 2023 (%)
Figure 12 Asia-Pacific: Blood Plasma Derivatives Market Share, by Country, 2023 (%)
Figure 13 Middle East & Africa: Blood Plasma Derivatives Market Share, by Country, 2023 (%)
Figure 14 Global Blood Plasma Derivatives Market: Company Share Analysis, 2023 (%)
Figure 15 Baxter BioScience: Key Financial Overview
Figure 16 Baxter BioScience: Segmental Revenue
Figure 17 Baxter BioScience: Geographic Revenue
Figure 18 Grifols S.A.: Key Financial Overview
Figure 19 Grifols S.A.: Segmental Revenue
Figure 20 Grifols S.A.: Geographic Revenue
Figure 21 CSL Behring: Key Financial Overview
Figure 22 CSL Behring: Segmental Revenue
Figure 23 CSL Behring: Geographic Revenue
Figure 24 ViroPharma, Inc.: Key Financial Overview
Figure 25 ViroPharma, Inc.: Segmental Revenue
Figure 26 ViroPharma, Inc.: Geographic Revenue
Figure 27 Talecris Biotherapeutics, Inc.: Key Financial Overview
Figure 28 Talecris Biotherapeutics, Inc.: Segmental Revenue
Figure 29 Talecris Biotherapeutics, Inc.: Geographic Revenue
Figure 30 Octapharma: Key Financial Overview
Figure 31 Octapharma: Segmental Revenue
Figure 32 Octapharma: Geographic Revenue
Figure 33 Fusion Healthcare: Key Financial Overview
Figure 34 Fusion Healthcare: Segmental Revenue
Figure 35 Fusion Healthcare: Geographic Revenue
Figure 36 SK Plasma Co., Ltd.: Key Financial Overview
Figure 37 SK Plasma Co., Ltd.: Segmental Revenue
Figure 38 SK Plasma Co., Ltd.: Geographic Revenue
Figure 39 Biotest AG: Key Financial Overview
Figure 40 Biotest AG: Segmental Revenue
Figure 41 Biotest AG: Geographic Revenue
Figure 42 Green Cross Corporation: Key Financial Overview
Figure 43 Green Cross Corporation: Segmental Revenue
Figure 44 Green Cross Corporation: Geographic Revenue
Figure 45 Shire Plc: Key Financial Overview
Figure 46 Shire Plc: Segmental Revenue
Figure 47 Shire Plc: Geographic Revenue
